{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-24-000604","form_type":"8-K","ticker":null,"cik":"0001476963","company_name":"Scorpius Holdings, Inc.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.580995+00:00","generated_at":"2026-06-03T05:29:51.185368+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Scorpius Holdings reports FY2023 net loss $45.2M, Q4 revenue up 570% sequentially, going concern warning","bullets":["FY2023 contract revenue $6.6M (vs $0.1M in 2022); Q4 2023 revenue $4.8M, a 570% sequential increase from Q3.","Net loss attributable to Scorpius $45.2M ($1.74 per share) vs $43.4M ($1.70) in 2022.","Cash and equivalents $2.4M as of December 31, 2023.","Auditor includes going concern opinion due to recurring losses and lack of significant revenue or positive cash flows.","Management expects to become cash flow positive by early 2025; over $20M in contract bookings recorded."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-24-000604","json":"https://secwatch.observer/filing/0001079973-24-000604.json","markdown":"https://secwatch.observer/filing/0001079973-24-000604.md","text":"https://secwatch.observer/filing/0001079973-24-000604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1476963/000107997324000604/0001079973-24-000604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1476963/000107997324000604/scpx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:29:51.185368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55fb027d992f80f5e2600c298306a203c5f0b558","claim":"Scorpius Holdings, Inc. reported the year ended December 31, 2023 results: revenue $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royal, net income approximately $45.2 million, or ($1.74) per basic and diluted share, EPS ($1.74) per basic and diluted share.","evidence_excerpt":"For the year ended December 31, 2023, the Company recognized $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royalty revenue from continuing operations.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1476963/000107997324000604/0001079973-24-000604-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royal"},{"label":"Net income","value":"approximately $45.2 million, or ($1.74) per basic and diluted share"},{"label":"EPS","value":"($1.74) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}